You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Antibody titers and protection against SG-MCMV challenge in mice immunized with various doses of FI-MCMV with or without adjuvant by i.m. injection a

From: An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV

Immunogen FI-MCMV ELISA titer (2n) of IgG antibodyb Protection against SG-MCMV challenge
Dosage (μg) Immunization once Immunization twice Spleen virus titers (log10PFU/ml) Survival mice/tested mice
Adjuvant-free 0.25 3.67 ± 1.15 5.33 ± 0.58 5.27 ± 0.19 0/6
+ Chitosan   5.00 ± 1.00 9.67 ± 1.15c 5.08 ± 0.13 0/6
+ Alum   6.33 ± 1.53c 11.33 ± 1.15c 5.14 ± 0.11 0/6
+ MF59   7.33 ± 0.58c 12.33 ± 1.53c 4.58 ± 0.36c,e 2/6
Adjuvant-free 1 4.67 ± 1.15 10.00 ± 1.73 5.13 ± 0.29 0/6
+ Chitosan   6.33 ± 0.58 12.00 ± 1.00c 4.64 ± 0.50e 2/6
+ Alum   7.33 ± 0.58c 12.33 ± 1.15c 4.78 ± 0.15e 1/6
+ MF59   10.67 ± 1.15c,d 15.00 ± 1.00c,d 3.51 ± 0.49c,d,e 5/6e
Adjuvant-free 4 7.67 ± 0.58 11.67 ± 1.52 4.41 ± 0.48e 3/6
+ Chitosan   10.00 ± 1.73c 13.67 ± 0.58c 4.02 ± 0.51e 5/6e
+ Alum   10.33 ± 0.58c 14.00 ± 1.00c 3.80 ± 0.11c,e 6/6e
+ MF59   11.67 ± 0.58c 16.33 ± 0.58c,d 2.56 ± 0.77c,d,e 6/6e
Chitosan only - Undetected Undetected 5.87 ± 0.17 0/6
Alum only   Undetected Undetected 5.68 ± 0.27 0/6
MF59 only   Undetected Undetected 5.62 ± 0.38 0/6
Mock   Undetected Undetected 5.73 ± 0.34 0/6
PBS   - - 5.91 ± 0.39 0/6
  1. aThe mice were immunized twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan) by i.m. injection. Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Three weeks after immunization, all the mice were challenged with a lethal dose of SG-MCMV. Spleen virus titers 5 days after challenge and survival rates of mice 21 days post-infection were determined. Results are expressed as means ± SD of tested mice in each group.
  2. bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
  3. cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
  4. dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
  5. eSignificant difference (p < 0.05), compared with corresponding control subjects.